Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of “Buy” by Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given an average rating of “Buy” by the fifteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $137.0769.

A number of research firms have recently commented on MIRM. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Leerink Partners cut their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday. Citizens Jmp restated a “market outperform” rating and issued a $132.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Finally, Wolfe Research began coverage on Mirum Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $145.00 price objective on the stock.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $3,769,800.30. Following the completion of the sale, the chief executive officer owned 194,309 shares in the company, valued at approximately $17,872,541.82. This trade represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jolanda Howe sold 4,732 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $435,249.36. Following the completion of the sale, the senior vice president owned 8,429 shares of the company’s stock, valued at approximately $775,299.42. This trade represents a 35.95% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 76,806 shares of company stock valued at $7,064,616. Company insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently modified their holdings of the stock. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. MCF Advisors LLC grew its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $32,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $32,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $33,000.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $98.62 on Friday. The stock’s 50-day moving average is $96.20 and its 200-day moving average is $88.41. The company has a market cap of $6.01 billion, a price-to-earnings ratio of -7.25 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals has a 12 month low of $42.89 and a 12 month high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.30) earnings per share. Equities analysts anticipate that Mirum Pharmaceuticals will post -2.11 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.